update, page-56

Often many walks of life come into the OBJ threads and have issues with lack of detail\forthcoming statements or confidentiality. Further this translates into long lead times were the share price sits dormant or retracts. It's a natural thing to become disenchanted and especially if your 'plans' do not match the OBJ share price appreciation you expected. It is biotech and like any industry time frames are difficult when science is involved and commercialisation with a joint partner can throw up many issues.

I'll give you all one live example that is currently being played out by GSK with a biotech partner. This partner is also into patch technology. I wont spell it out, I'll let you read the links I give and let you join the linkages - these are no dots!!! Please take the time to see the time frame of this development and you just never know, OBJ may or may not be in this situation in the future.

http://www.prosensa.eu/press-release/prosensa-and-glaxosmithkline-form-alliance-fight-duchenne-muscular-dystrophy

http://www.muscular-dystrophy.org/research/news/2415_prosensa_and_gsk_announce_plans_to_further_develop_exon_skipping_for_duchenne

http://www.gsk-clinicalstudyregister.com/quick-search-list.jsp?tab=protocols&phase=All&studyType=All&population=All&marketing=No&status=All&country=All&item=GSK2402968&letterrange=G-K&type=Compound

Page 19 shows you were this is at for 2012 Q1 results:

http://www.gsk.com/investors/quarterly_results.htm

So I sit back, relax and hold. As I said probably 12 months back - I have placed my kids money (their future) is in this coy as I believe in the technology, understand were drug delivery technology is heading for the future and with OBJ's MC I am very comfortable.